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Summary
Background Associations of larger families with lower prevalences of hay fever, eczema
and objective markers of allergic sensitization have been found fairly consistently in
affluent countries, but little is known about these relationships in less affluent countries.
Methods Questionnaire data for 210 200 children aged 6–7 years from 31 countries, and
337 226 children aged 13–14 years from 52 countries, were collected by Phase Three of
the International Study of Asthma and Allergies in Childhood (ISAAC). Associations of
disease symptoms and labels of asthma, rhinoconjunctivitis and eczema were analysed by
numbers of total, older and younger siblings, using mixed (multi-level) logistic regression
models to adjust for individual covariates and at the centre level for region, language and
national affluence.
Results In both age groups, inverse trends (P < 0.0001) were observed for reported ‘hay
fever ever’ and ‘eczema ever’ with increasing numbers of total siblings, and more specifi-
cally older siblings. These inverse associations were significantly (P < 0.005) stronger in
more affluent countries. In contrast, symptoms of severe asthma and severe eczema were
positively associated (P < 0.0001) with total sibship size in both age groups. These associ-
ations with disease severity were largely independent of position within the sibship and
national GNI per capita.
Conclusions These global findings on sibship size and childhood asthma, rhinoconjuncti-
vitis and eczema suggest at least two distinct trends. Inverse associations with older sib-
lings (observations which prompted the ‘hygiene hypothesis’ for allergic disease) are
mainly a phenomenon of more affluent countries, whereas greater severity of symptoms
in larger families is globally more widespread.
Keywords allergic rhinitis, asthma, atopic dermatitis, birth order, eczema, hay fever, inter-
national, siblings
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Introduction
More than two decades have elapsed as an inverse asso-
ciation was reported between numbers of siblings (par-
ticularly older siblings) and the parentally reported
prevalence of hay fever and eczema in two British
national cohorts, born in 1970 [1] and 1958 [2]. These
observations, since replicated very widely in affluent
countries [3–27], prompted the hypothesis that the ris-
ing prevalence of allergic diseases may be due to a
reduction in exposure to infections in modern industri-
alized societies [2].
The epidemiological associations which underpin this
‘hygiene hypothesis’ have not been studied so extensively
*ISAAC Phase Three Study Group members are presented in the
Appendix 1.
†Died 27 October 2012.
in less affluent countries. The International Study of
Asthma and Allergies in Childhood (ISAAC, http://isaac.
auckland.ac.nz/) provides a unique global perspective on
asthma, rhinoconjunctivitis and eczema. In this paper, we
present the associations of sibship size and position
within the sibship with both current symptoms and life-
time labelling of these three conditions, among both
younger and older children.
Methods
Phase Three of ISAAC has been described in detail else-
where [28]. In brief, each study centre performed a
cross-sectional questionnaire survey of 13 to 14-year-
old adolescents and (optionally) 6 to 7-year-old chil-
dren, using a cluster sample design with schools as the
primary sampling unit (cluster). Parents completed writ-
ten questionnaires on behalf of the younger children,
while the adolescents completed written questionnaires
themselves at school. Questionnaires were translated
from English into the local language and back-trans-
lated for validation prior to fieldwork. Ethics committee
approvals were obtained locally.
Symptom prevalence, severity and disease labels were
ascertained by the ISAAC core symptom questionnaires
[28]. Following conventions set in previous ISAAC
Phase Three analyses, the following combinations of
responses were used to define ‘current’ and ‘severe’
symptoms of asthma, rhinoconjunctivitis and eczema:
• Current asthma symptoms: wheezing or whistling in
the chest in the past 12 months.
• Severe asthma symptoms: in the past 12 months,
either four or more attacks of wheezing and/or sleep
disturbed due to wheezing one or more nights per
week on average and/or wheeze-limiting speech to
only one or two words at a time between breaths.
• Current rhinoconjunctivitis: in the past 12 months, a
problemwith sneezing, or a runnyor blocked nosewhen
you/he/she did not have a cold or the ‘flu, and this nose
problemwasaccompaniedby itchywateryeyes.
• Severe rhinoconjunctivitis: In the past 12 months, this
nose problem interfered with daily activities a lot.
• Current eczema symptoms: an itchy rash which at
any time was coming and going for at least
6 months had at any time affected the folds of the
elbows, behind the knees, in front of the ankles,
under the buttocks, or around the neck, ears or eyes,
and was present at any time in the past 12 months.
• Severe eczema symptoms: in the past 12 months,
kept awake at night one or more nights per week on
average by this itchy rash.
Additional analyses were carried out for lifetime
histories (as reported in the cross-sectional survey) of
wheeze, non-infective rhinitis, itchy rash, asthma, hay
fever and eczema. These correspond to the first and last
questions within each section of the core questionnaire
and were asked of all subjects (i.e. without stem-and-
branch structure):
• Wheeze ever: ever had wheezing or whistling in the
chest.
• Asthma ever: ever had asthma.
• Rhinitis ever: ever had a problem with sneezing, or a
runny or blocked nose when you/he/she did not
have a cold or the ‘flu.
• Hay fever ever: ever had hay fever.
• Itchy rash ever: ever had an itchy rash which at any
time was coming and going for at least 6 months.
• Eczema ever: ever had eczema.
The symptom questionnaire was followed (at the dis-
cretion of the study centre) by a risk factor (‘environmen-
tal’) questionnaire which included questions about the
number of older brothers and sisters, and younger broth-
ers and sisters. These were combined into a ‘total siblings’
variable for analysis. Numbers of total, older and youn-
ger siblings were each analysed in four groups (0, 1, 2, 3
or more) for the purposes of both categorical and trend
analyses. When assessing the trend in prevalence by
number of older siblings, the number of younger siblings
was included as a categorical covariate, and vice versa.
Centres where more than 30% of children had missing
data on sibship size were excluded from the analysis.
Statistical analyses used a two-level multiple logistic
regression model, implemented in SAS PROC GLIMMIX
(SAS Institute Inc., Cary, NC, USA). This allowed simul-
taneous adjustment for both individual-level and cen-
tre-level covariates. Basic analyses adjusted for gender
at the individual level and for WHO region, language
and national affluence at the centre level. Affluence
was measured by the World Bank 2001 statistics on
Gross National Income (GNI) per person [29]. Following
conventions set by previous ISAAC Phase Three analy-
ses, adjustments were made to the effective sample size
(design effect) for each symptom or disease outcome,
based on the within-school (intra-cluster) correlation
observed for each outcome within each centre and age
group.
Due to the large sample sizes in each age group and
the multiple inter-related comparisons being made, the
presentation and discussion will focus upon results that
are significant at the 1% level (P < 0.01) and particu-
larly on those significant at the 0.01% level
(P < 0.0001).
Results
Information about sibship size and symptoms was
available for 210 200 children aged 6–7 years from 74
centres in 31 countries, and for 337 226 adolescents
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aged 13–14 years from 116 centres in 52 countries. In
the younger age group, 17% of children had no broth-
ers or sisters, 44% had one, 23% had two and 17% had
three or more siblings. Among the adolescents, the cor-
responding figures were 11%, 32%, 25% and 32%,
respectively.
When the centres were subdivided according to
national per capita income (GNI, using the World Bank
2001 classification of ‘high’ vs. the remainder), the
younger age group comprised 67 026 children from 24
centres in 10 affluent countries and 143 174 children
from 50 centres in 21 less affluent countries. The older
age group comprised 101 082 adolescents from 33 cen-
tres in 16 affluent countries and 236 144 adolescents
from 83 centres in 36 less affluent countries. Most of
the affluent countries are located at latitudes where sea-
sonal fluctuations in outdoor aeroallergen levels are
expected, whereas many of the less affluent countries
lie within the tropics, where the concept of hay fever or
seasonal allergic rhinitis may be less relevant.
Table 1 shows the association between total number
of siblings and each symptom or disease outcome, for
each age group, expressed both as comparisons with
the zero siblings group and as a significance test for
trend in odds ratios. Highly significant (P < 0.0001)
trends of lower prevalence with increasing sibship size
were observed in both age groups for a lifetime history
of hay fever and for a lifetime history of eczema, with
a less significant (P < 0.001) trend for asthma ever in
the adolescents, but not for asthma ever in the younger
age group. In contrast, children with more siblings were
less likely to have a history of wheeze ever in both age
groups, whereas the inverse associations with rhinitis
ever and with itchy rash ever were not consistent
between younger children and adolescents. Although
current symptoms were generally not significantly asso-
ciated with sibship size, the exception was current flex-
ural dermatitis which showed a trend (P < 0.01) to be
more common in larger families. However, severe
asthma symptoms and severe eczema symptoms were
highly significantly (P < 0.0001) associated with larger
sibships, in both age groups. The association of sibship
size with severe rhinoconjunctivits was weaker and not
significant at the 1% level in either age group.
Table 2 shows the odds ratios associated with each
additional older sibling, adjusting for the number of
younger siblings (as a categorical covariate) and vice
versa. The inverse associations of total siblings with
hay fever ever and with eczema ever were more
strongly influenced by older siblings: relative reduc-
tions of about 10% per older sibling in the younger age
group and about 5% per older sibling in the adoles-
cents. These effects of position within the sibship were
highly significant, after adjustment for the number of
younger siblings (thus, independent of total sibship
size). In the older age group, there was a weaker ‘pro-
tective’ influence of younger siblings, independent of
older siblings, a trend which was statistically significant
(P < 0.01) for hay fever but not for eczema. The inverse
trend with younger siblings was significantly weaker
than the trend with older siblings for eczema ever in
the children, and for hay fever ever in both age groups.
In contrast, the increased risk of severe asthma and
severe eczema symptoms in larger families was attribut-
able in approximately equal measure to older and to
younger siblings (Table 2). There were no significant
differences between the effects of older and younger
siblings on these more severe symptoms.
Table 3 compares the per-sibling odds ratios from the
total sibship size analyses for centres in affluent coun-
tries and centres in non-affluent countries. Generally,
the inverse associations with disease labels were con-
centrated mainly in the affluent countries, whereas the
positive associations with disease severity were found
in both affluent and non-affluent countries. There were
significant differences (P < 0.001) between affluent and
non-affluent centres for the sibship size effects on hay
fever ever and eczema ever in both age groups.
Table 4 explores the association of total sibship size
with current and severe symptoms, after stratifying the
children according to the relevant disease label (asthma
ever for asthma symptoms, hay fever ever for rhinocon-
junctivitis and eczema ever for eczema symptoms). In
both age groups, the associations of larger families with
severe asthma and severe eczema were present both
among children with the relevant disease label, and
among children without this label. After stratification
by disease label, these positive associations of severity
with sibship size generally strengthened and became
even more highly significant than in the unstratified
analyses shown in the left-hand columns of Table 3.
Table 5 compares the effect of total siblings on each
outcome before and after adjustment for a range of
potential confounding variables in the younger age
group. This analysis was restricted to the younger chil-
dren because there were a wider range of covariates
ascertained from the parental questionnaire, particularly
those relating to early childhood. The following ‘current
exposures’ were considered as confounders for total sib-
lings – gender, maternal education, mother or father
smoking currently (i.e. at age 6–7), current cat and dog
ownership, truck traffic exposure and current cooking
fuels. The following ‘early-life’ factors were considered
as confounders for older siblings – gender, maternal
education, mother smoking in the first year, cat, dog
and farm animal exposure in the first year, birth
weight, breastfeeding, paracetamol use in the first year
and antibiotic use in the first year.
The results shown in Table 5 are derived from
135 250 six to seven-year-old children with complete
© 2014 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd., 45 : 126–136
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covariate data, from 55 centres in 21 countries. The
patterns of unadjusted results were very similar in this
subset, compared to the total sample, and the effect of
adjustment was minimal, both for the total sibling
effects and the associations with numbers of older sib-
lings.
Discussion
This study, of over half a million children from diverse
study centres worldwide, provides the most comprehen-
sive assessment to date of the association of symptoms
of asthma, rhinoconjunctivitis and eczema with total
number of siblings and with position within the sibship.
The findings from adolescents and younger children
were generally consistent and suggest at least two dis-
tinct trends. Inverse associations of total sibship size
with disease labels (particularly for hay fever and
eczema) are largely attributable to the number of older
siblings and are mainly a phenomenon of more affluent
countries. In contrast, the greater prevalence of more
severe symptoms of asthma and eczema in larger fami-
lies is globally more widespread, and related to total
numbers of brothers and sisters, rather than to position
in the sibship.
The strengths of ISAAC lie in its size and the diver-
sity of the participating centres. In such a large total
sample size, quite subtle associations can be statistically
significant at the conventional 5% level. We have con-
centrated on the more extreme P values and the
strength of associations, and the more consistent and
contrasting patterns across disease outcomes, age
groups and study centres, ranked according to national
GNI per capita.
An important limitation is that this ISAAC Phase
Three study is based entirely on questionnaire data.
However, in Phase Two of ISAAC, among 9 to 11-year-
old children from 30 centres, in 22 countries worldwide
(including seven non-affluent countries and three coun-
tries from Eastern Europe), written symptom question-
naires were supplemented by skin prick tests for
sensitization to six common aeroallergens [30]. When
skin prick test positivity to any allergen was analysed
in relation to total number of siblings within each cen-
tre and combined by random-effects meta-analysis, the
pooled odds ratio for skin test positivity per additional
Table 1. Association of symptoms and disease labels with total number of siblings, odds ratios by category and test for trend
No siblings
OR (95% CL)
One sibling (vs. none)
OR (95% CL)
Two siblings (vs. none)
OR (95% CL)
Three or more
siblings (vs. none)
OR (95% CL)
Trend
P value
Symptom (6 to 7-year-olds)
Wheeze ever 1.00 (reference) 0.99 (0.95, 1.03) 0.93 (0.89, 0.98) 0.89 (0.84, 0.94) < 0.0001
Wheeze in last 12 months 1.00 (reference) 0.99 (0.94, 1.04) 0.96 (0.91, 1.02) 0.99 (0.92, 1.05) 0.35
Severe wheeze in last 12 months 1.00 (reference) 0.99 (0.92, 1.07) 1.05 (0.97, 1.14) 1.19 (1.09, 1.30) < 0.0001
Asthma ever 1.00 (reference) 1.02 (0.97, 1.08) 0.95 (0.89, 1.01) 0.98 (0.92, 1.05) 0.11
Rhinitis ever 1.00 (reference) 0.96 (0.92, 1.00) 0.87 (0.83, 0.91) 0.86 (0.82, 0.90) < 0.0001
Rhinoconjunctivitis in last 12 months 1.00 (reference) 1.00 (0.95, 1.06) 0.95 (0.90, 1.01) 0.96 (0.90, 1.04) 0.09
Severe rhinoconjunctivitis 1.00 (reference) 1.03 (0.86, 1.23) 1.01 (0.83, 1.23) 1.15 (0.92, 1.43) 0.32
Hay fever ever 1.00 (reference) 0.97 (0.91, 1.02) 0.85 (0.79, 0.90) 0.81 (0.75, 0.87) < 0.0001
Itchy rash ever 1.00 (reference) 1.04 (1.00, 1.09) 1.00 (0.95, 1.05) 1.02 (0.96, 1.08) 0.82
Itchy flexural rash in last 12 months 1.00 (reference) 1.09 (1.03, 1.15) 1.01 (0.95, 1.08) 1.04 (0.97, 1.12) 0.91
Severe itchy flexural rash 1.00 (reference) 1.04 (0.89, 1.22) 1.14 (0.96, 1.35) 1.63 (1.36, 1.95) < 0.0001
Eczema ever 1.00 (reference) 1.03 (0.98, 1.08) 0.92 (0.87, 0.97) 0.81 (0.75, 0.86) < 0.0001
Symptom (13 to 14-year-olds)
Wheeze ever 1.00 (reference) 0.94 (0.89, 0.99) 0.92 (0.87, 0.98) 0.90 (0.85, 0.96) 0.002
Wheeze in last 12 months 1.00 (reference) 0.96 (0.90, 1.03) 0.98 (0.92, 1.05) 0.97 (0.91, 1.04) 0.82
Severe wheeze in last 12 months 1.00 (reference) 0.96 (0.88, 1.03) 1.05 (0.97, 1.14) 1.14 (1.05, 1.24) < 0.0001
Asthma ever 1.00 (reference) 0.96 (0.91, 1.02) 0.94 (0.89, 1.00) 0.91 (0.85, 0.96) 0.006
Rhinitis ever 1.00 (reference) 0.96 (0.91, 1.00) 0.94 (0.89, 0.99) 0.97 (0.92, 1.02) 0.58
Rhinoconjunctivitis in last 12 months 1.00 (reference) 0.97 (0.91, 1.03) 0.96 (0.90, 1.02) 1.03 (0.96, 1.09) 0.12
Severe rhinoconjunctivitis 1.00 (reference) 0.93 (0.78, 1.11) 0.89 (0.75, 1.07) 1.09 (0.91, 1.30) 0.07
Hay fever ever 1.00 (reference) 0.92 (0.86, 0.97) 0.86 (0.81, 0.91) 0.82 (0.77, 0.88) < 0.0001
Itchy rash ever 1.00 (reference) 0.93 (0.88, 0.99) 0.94 (0.89, 1.00) 1.03 (0.97, 1.10) 0.009
Itchy flexural rash in last 12 months 1.00 (reference) 0.91 (0.85, 0.98) 0.96 (0.88, 1.03) 1.05 (0.97, 1.13) 0.001
Severe itchy flexural rash 1.00 (reference) 0.96 (0.81, 1.15) 1.09 (0.91, 1.30) 1.33 (1.11, 1.58) < 0.0001
Eczema ever 1.00 (reference) 0.95 (0.89, 1.01) 0.90 (0.84, 0.96) 0.88 (0.82, 0.94) < 0.0001
All analyses are adjusted for gender, region, language and national GNI per capita.
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sibling was 0.93 (95% CI 0.90–0.97). This is very similar
to the corresponding per-sibling odds ratios for hay
fever ever and eczema ever in Phase Three (Table 2),
suggesting that the latter are not simply a labelling
artefact, but evidence of an underlying biological effect,
as reported in other studies [3, 27].
Sibship size is not necessarily the same as household
size, and patterns of child contact may be influenced as
much by local customs in child care and schooling as
by the size of the household. What is meant by ‘brother’
and ‘sister’ may also be culturally determined. These
uncertainties would tend to attenuate any true associa-
tion with sibship size or position within the sibship,
whereas the principal associations that we observed are
not only strong but also display differences in their epi-
demiological patterns. There is a relative specificity of
protective influences from older siblings, contrasting
with similar adverse influences on severity from older
and younger siblings.
The major confounding factors for older siblings and
total siblings differ substantially, as biomedical influ-
ences associated with birth order are only weakly
correlated with total siblings, whereas most socioeco-
nomic and lifestyle confounders that are correlated with
total family size are not independently associated with
position within the sibship. However, when our results
were adjusted for a range of ‘current’ confounders (for
total sibship size) and ‘early-life’ confounders (for older
siblings), the trends remained virtually unchanged.
Although measurement error in the covariates may
have reduced the rigour of this adjustment, the robust-
ness of the sibship size associations suggests that their
underlying explanations lie in factors unrelated to those
included in our models.
Most previous ISAAC reports have concentrated on
current symptoms and selected measures of severity.
We used the severity markers for asthma symptoms and
eczema symptoms that were developed for earlier
ISAAC publications [31, 32], and both of these include
sleep disturbance. As it is possible that sleep may be
disturbed by other children, particularly if they share a
bedroom, we examined alternative measures of severity
that excluded night waking. For instance, the odds ratio
per additional sibling for one or more episodes of
Table 2. Association of symptoms and disease labels with numbers of older and younger siblings (mutually adjusted)
Older siblings (per additional
sibling) adjusted for younger
siblings
Younger siblings (per
additional sibling) adjusted
for older siblings
Comparison of trends
for older and younger
siblings
OR (95% CL) P value OR (95% CL) P value P value
Symptom (6 to 7-year-olds)
Wheeze ever 0.97 (0.95, 0.98) < 0.0001 0.96 (0.94, 0.98) 0.0003 0.82
Wheeze in last 12 months 1.01 (0.99, 1.03) 0.38 0.96 (0.93, 0.98) 0.0008 0.001
Severe wheeze in last 12 months 1.07 (1.04, 1.10) < 0.0001 1.04 (1.01, 1.08) 0.02 0.25
Asthma ever 0.99 (0.97, 1.01) 0.27 0.98 (0.96, 1.01) 0.23 0.81
Rhinitis ever 0.93 (0.91, 0.94) < 0.0001 1.03 (1.01, 1.05) 0.006 < 0.0001
Rhinoconjunctivitis in last 12 months 0.98 (0.96, 1.00) 0.03 1.03 (1.00, 1.06) 0.04 0.003
Severe rhinoconjunctivitis 1.00 (0.93, 1.07) 0.89 1.11 (1.02, 1.21) 0.01 0.05
Hay fever ever 0.91 (0.89, 0.93) < 0.0001 1.00 (0.97, 1.02) 0.74 < 0.0001
Itchy rash ever 0.98 (0.96, 1.00) 0.02 1.06 (1.04, 1.09) < 0.0001 < 0.0001
Itchy flexural rash in last 12 months 0.98 (0.96, 1.00) 0.09 1.06 (1.03, 1.09) < 0.0001 < 0.0001
Severe itchy flexural rash 1.14 (1.08, 1.20) < 0.0001 1.20 (1.12, 1.28) < 0.0001 0.22
Eczema ever 0.90 (0.88, 0.92) < 0.0001 1.03 (1.01, 1.06) 0.02 < 0.0001
Symptom (13 to 14-year-olds)
Wheeze ever 0.97 (0.96, 0.99) 0.0005 0.99 (0.97, 1.01) 0.27 0.12
Wheeze in last 12 months 0.99 (0.97, 1.01) 0.26 1.10 (0.99, 1.03) 0.43 0.19
Severe wheeze in last 12 months 1.04 (1.02, 1.07) 0.0001 1.07 (1.04, 1.09) < 0.0001 0.13
Asthma ever 0.97 (0.96, 0.99) 0.0003 0.99 (0.97, 1.01) 0.36 0.09
Rhinitis ever 1.00 (0.98, 1.01) 0.65 1.01 (0.99, 1.02) 0.50 0.41
Rhinoconjunctivitis in last 12 months 1.00 (0.99, 1.02) 0.71 1.03 (1.01, 1.05) 0.004 0.05
Severe rhinoconjunctivitis 1.03 (0.99, 1.08) 0.15 1.07 (1.02, 1.13) 0.004 0.24
Hay fever ever 0.94 (0.93, 0.96) < 0.0001 0.97 (0.96, 0.99) 0.006 0.02
Itchy rash ever 1.02 (1.01, 1.04) 0.06 1.02 (1.00, 1.04) 0.03 0.81
Itchy flexural rash in last 12 months 1.03 (1.01, 1.05) 0.01 1.03 (1.01, 1.06) 0.004 0.66
Severe itchy flexural rash 1.12 (1.07, 1.16) < 0.0001 1.10 (1.05, 1.14) < 0.0001 0.55
Eczema ever 0.96 (0.95, 0.98) < 0.0001 0.98 (0.96, 1.00) 0.06 0.28
All analyses are adjusted for sex, region, language and national GNI per capita.
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Table 3. Association of total number of siblings with symptoms and disease labels in affluent and non-affluent centres
Total siblings (per additional
sibling) Affluent centres*
Total siblings (per additional
sibling) Non-affluent centres*
Comparison
of trends
in affluent and
non-affluent
centres
OR (95% CL) P value OR (95% CL) P value P value
Symptom (6 to 7-year-olds)
Wheeze ever 0.94 (0.91, 0.96) < 0.0001 0.98 (0.96, 1.00) 0.02 0.01
Wheeze in last 12 months 0.96 (0.93, 0.99) 0.007 1.01 (0.99, 1.04) 0.33 0.006
Severe wheeze in last 12 months 1.02 (0.98, 1.07) 0.36 1.09 (1.05, 1.13) < 0.0001 0.03
Asthma ever 0.97 (0.94, 1.00) 0.08 0.99 (0.96, 1.02) 0.54 0.37
Rhinitis ever 0.92 (0.89, 0.94) < 0.0001 0.96 (0.94, 0.98) 0.0001 0.002
Rhinoconjunctivitis in last 12 months 0.90 (0.87, 0.93) < 0.0001 1.03 (1.01, 1.06) 0.02 < 0.0001
Severe rhinoconjunctivitis 0.99 (0.88, 1.12) 0.09 1.06 (0.97, 1.15) 0.18 0.39
Hay fever ever 0.87 (0.84, 0.91) < 0.0001 0.96 (0.93, 0.99) 0.003 0.0001
Itchy rash ever 1.00 (0.97, 1.03) 0.88 1.00 (0.98, 1.02) 0.84 0.99
Itchy flexural rash in last 12 months 0.98 (0.95, 1.01) 0.24 1.01 (0.98, 1.04) 0.45 0.16
Severe itchy flexural rash 1.16 (1.05, 1.28) 0.003 1.18 (1.10, 1.27) < 0.0001 0.80
Eczema ever 0.90 (0.88, 0.93) < 0.0001 0.96 (0.93, 0.99) 0.005 0.003
Symptom (13 to 14-year-olds)
Wheeze ever 0.99 (0.96, 1.02) 0.42 0.96 (0.94, 0.98) 0.0006 0.09
Wheeze in last 12 months 1.01 (0.98, 1.04) 0.49 0.99 (0.96, 1.01) 0.36 0.25
Severe wheeze in last 12 months 1.08 (1.04, 1.12) 0.0002 1.06 (1.03, 1.09) 0.0002 0.52
Asthma ever 0.96 (0.94, 0.99) 0.005 0.98 (0.95, 1.00) 0.03 0.45
Rhinitis ever 0.98 (0.95, 1.00) 0.05 1.10 (0.99, 1.03) 0.39 0.04
Rhinoconjunctivitis in last 12 months 1.00 (0.98, 1.03) 0.84 1.02 (1.00, 1.05) 0.08 0.33
Severe rhinoconjunctivitis 1.05 (0.95, 1.16) 0.36 1.05 (0.99, 1.11) 0.13 0.97
Hay fever ever 0.91 (0.88, 0.93) < 0.0001 0.98 (0.95, 1.00) 0.07 0.0001
Itchy rash ever 0.99 (0.97, 1.02) 0.67 1.05 (1.02, 1.07) 0.0003 0.009
Itchy flexural rash in last 12 months 1.03 (1.00, 1.07) 0.09 1.04 (1.01, 1.07) 0.01 0.81
Severe itchy flexural rash 1.18 (1.08, 1.28) 0.0003 1.12 (1.06, 1.19) < 0.0001 0.36
Eczema ever 0.93 (0.90, 0.95) < 0.0001 1.00 (0.97, 1.03) 0.77 0.0006
*Affluent centres: centres in countries with ‘high’ GNI per capita as defined by World Bank, 2001; Non-affluent centres: all other centres.
Table 4. Association of total number of siblings with symptoms in subjects with and without the relevant disease label
Total siblings (per additional
sibling) Subjects with relevant
disease label ever*
Total siblings (per additional
sibling) Subjects without
relevant disease label ever*
Comparison of trends
for subjects with and
without relevant
disease label
OR (95% CL) P value OR (95% CL) P value P value
Symptom (6 to 7-year-olds)
Wheeze in last 12 months 1.02 (0.98, 1.06) 0.36 0.98 (0.96, 1.01) 0.22 0.14
Severe wheeze in last 12 months 1.07 (1.03, 1.12) 0.0009 1.10 (1.05, 1.15) < 0.0001 0.39
Rhinoconjunctivitis in last 12 months 1.00 (0.97, 1.04) 0.89 1.04 (1.01, 1.07) 0.01 0.14
Severe rhinoconjunctivitis 1.11 (1.02, 1.21) 0.01 1.06 (0.94, 1.19) 0.34 0.49
Itchy flexural rash in last 12 months 1.06 (1.02, 1.10) 0.001 1.02 (0.99, 1.05) 0.22 0.11
Severe itchy flexural rash 1.22 (1.13, 1.32) < 0.0001 1.24 (1.13, 1.35) < 0.0001 0.87
Symptom (13 to 14-year-olds)
Wheeze in last 12 months 1.01 (0.98, 1.05) 0.55 1.02 (0.99, 1.04) 0.21 0.83
Severe wheeze in last 12 months 1.08 (1.04, 1.12) < 0.0001 1.11 (1.07, 1.14) < 0.0001 0.28
Rhinoconjunctivitis in last 12 months 1.04 (1.01, 1.07) 0.02 1.03 (1.01, 1.06) 0.009 0.78
Severe rhinoconjunctivitis 1.07 (1.01, 1.15) 0.03 1.07 (0.99, 1.16) 0.09 0.97
Itchy flexural rash in last 12 months 1.06 (1.02, 1.10) 0.003 1.05 (1.02, 1.08) 0.002 0.71
Severe itchy flexural rash 1.11 (1.04, 1.19) 0.003 1.19 (1.11, 1.28) < 0.0001 0.13
*Relevant disease label: asthma ever (for wheeze symptoms), hay fever ever (for rhinitis symptoms), eczema ever (for itchy rash symptoms).
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speech-limiting wheeze in the last 12 months was 1.12
(95% CI 1.07–1.17) in the younger children, and 1.10
(1.07–1.13) in the older age group. Also, the per-sibling
odds ratios for itchy rash which did not clear during
the last 12 months were 1.09 (1.06–1.12) at age 6–7
and 1.08 (1.05–1.11) among adolescents. Thus, the sig-
nificant associations with more severe disease shown in
Table 3 are not solely attributable to the sleep distur-
bance dimension.
Disease labels have not been a prominent feature
of previous ISAAC reports due to concerns about dif-
ferential use of clinical terms in different countries or
cultures. Here, however, the disease labels ‘hay fever
ever’ and ‘eczema ever’ display a different epidemiology
to that of current symptoms. An interesting and novel
feature of our analysis is the variation between coun-
tries with different levels of affluence in the protec-
tive effects of older siblings on hay fever ever and
eczema ever. Most of the affluent countries, in which
this effect is seen, lie outside the tropics, and the
type of seasonal allergic rhinitis that is termed ‘hay
fever’ may be mainly a phenomenon of temperate
climates. Thus, confounding of affluence by latitude
could be a contributing factor for the hay fever find-
ings. On the other hand, use of the term ‘eczema’ is
probably less prone to this type of climatic confound-
ing and shows a similar pattern to hay fever in both
age groups.
Table 5. Association of symptoms and disease labels with total and older siblings, before and after adjustment for covariates
Symptom (6 to 7-year-olds)
Total siblings (odds ratio per
additional sibling) All children
as in Table 1
Total siblings (odds ratio per
additional sibling) Before
adjustment, in children with
covariate data
Total siblings (odds ratio per
additional sibling) After
adjustment, in children with
covariate data
OR (95% CL) P value OR (95% CL) P value OR (95% CL) P value
Wheeze ever 0.96 (0.94, 0.98) < 0.0001 0.96 (0.94, 0.98) < 0.0001 0.96 (0.94, 0.98) < 0.0001
Wheeze in last 12 months 0.99 (0.97, 1.01) 0.35 0.99 (0.97, 1.02) 0.56 0.99 (0.96, 1.01) 0.19
Severe wheeze in last 12 months 1.06 (1.03, 1.09) < 0.0001 1.06 (1.02, 1.09) 0.0007 1.03 (1.00, 1.06) 0.07
Asthma ever 0.98 (0.96, 1.00) 0.11 0.99 (0.96, 1.01) 0.22 0.98 (0.96, 1.01) 0.12
Rhinitis ever 0.94 (0.93, 0.96) < 0.0001 0.94 (0.93, 0.96) < 0.0001 0.94 (0.93, 0.96) < 0.0001
Rhinoconjunctivitis in last 12 months 0.98 (0.96, 1.00) 0.09 0.99 (0.97, 1.01) 0.37 0.99 (0.97, 1.01) 0.36
Severe rhinoconjunctivitis 1.04 (0.97, 1.11) 0.31 1.05 (0.97, 1.13) 0.21 1.03 (0.95, 1.11) 0.48
Hay fever ever 0.92 (0.90, 0.95) < 0.0001 0.92 (0.89, 0.94) < 0.0001 0.92 (0.90, 0.95) < 0.0001
Itchy rash ever 1.00 (0.98, 1.02) 0.81 1.00 (0.98, 1.02) 0.67 1.00 (0.98, 1.02) 0.81
Itchy flexural rash in last 12 months 1.00 (0.98, 1.02) 0.91 1.00 (0.98, 1.03) 0.72 1.01 (0.98, 1.03) 0.59
Severe itchy flexural rash 1.18 (1.11, 1.24) < 0.0001 1.18 (1.11, 1.26) < 0.0001 1.13 (1.05, 1.20) 0.0004
Eczema ever 0.93 (0.91, 0.95) < 0.0001 0.93 (0.91, 0.95) < 0.0001 0.95 (0.93, 0.97) < 0.0001
Symptom (6 to 7-year-olds)
Older siblings (adjusted for
younger siblings) All children
as in Table 2
Older siblings (adjusted for
younger siblings) Before
adjustment, in children with
covariate data
Older siblings (adjusted for
younger siblings) After
adjustment, in children
with covariate data
OR (95% CL) P value OR (95% CL) P value OR (95% CL) P value
Wheeze ever 0.97 (0.95, 0.98) < 0.0001 0.97 (0.95, 0.99) 0.002 0.98 (0.96, 1.00) 0.04
Wheeze in last 12 months 1.01 (0.99, 1.03) 0.38 1.01 (0.99, 1.04) 0.43 1.01 (0.98, 1.04) 0.45
Severe wheeze in last 12 months 1.07 (1.04, 1.10) < 0.0001 1.06 (1.03, 1.10) 0.0009 1.05 (1.01, 1.09) 0.02
Asthma ever 0.99 (0.97, 1.01) 0.27 0.99 (0.96, 1.02) 0.52 1.00 (0.97, 1.03) 0.82
Rhinitis ever 0.93 (0.91, 0.94) < 0.0001 0.93 (0.91, 0.95) < 0.0001 0.93 (0.91, 0.95) < 0.0001
Rhinoconjunctivitis in last 12 months 0.98 (0.96, 1.00) 0.03 0.98 (0.96, 1.01) 0.25 0.99 (0.97, 1.02) 0.69
Severe rhinoconjunctivitis 1.00 (0.93, 1.07) 0.89 1.00 (0.91, 1.09) 0.92 1.01 (0.92, 1.10) 0.90
Hay fever ever 0.91 (0.89, 0.93) < 0.0001 0.90 (0.87, 0.93) < 0.0001 0.91 (0.88, 0.94) < 0.0001
Itchy rash ever 0.98 (0.96, 1.00) 0.23 0.97 (0.95, 0.99) 0.01 0.97 (0.95, 1.00) 0.03
Itchy flexural rash in last 12 months 0.98 (0.96, 1.00) 0.09 0.98 (0.96, 1.01) 0.19 0.98 (0.95, 1.01) 0.24
Severe itchy flexural rash 1.14 (1.08, 1.20) < 0.0001 1.14 (1.06, 1.22) 0.0004 1.09 (1.01, 1.18) 0.03
Eczema ever 0.90 (0.88, 0.92) < 0.0001 0.90 (0.88, 0.92) < 0.0001 0.92 (0.90, 0.94) < 0.0001
All analyses are adjusted for sex, region, language and national GNI per capita. Additional covariates for the total siblings analysis: gender,
maternal education, parental smoking, cat, dog, truck traffic and cooking fuels (all at age 6–7). Additional covariates for the older siblings analy-
sis: gender, maternal education, mother smoking in the first year of life, cat, dog and farm animal exposure in the first year, birthweight, breast-
feeding, paracetamol use in the first year, antibiotic use in the first year.
© 2014 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd., 45 : 126–136
132 D. P. Strachan et al.
The ‘hygiene hypothesis’ for allergic disease was
developed from observations on parental reports of ‘hay
fever’ and ‘eczema’ among their offspring in two British
birth cohorts [2]. More recent commentaries have sug-
gested not only that the immunological processes
underlying sibship size effects may extend to a wider
range of disease conditions [33–35], but also that mech-
anisms other than reduced exposure to infection may
need to be considered as explanations for the associa-
tions of asthma and allergies with family size and birth
order, even in higher-income countries [35–38].
The global perspective provided by ISAAC suggests a
more complex picture, with variations between less
affluent and more affluent countries, both in the immu-
nology of asthma, rhinoconjunctivitis and eczema in
children, and in their epidemiological determinants. In
ISAAC Phase Two, atopy (as measured by aeroallergen
skin prick tests) was less strongly associated with symp-
toms of asthma [39], rhinoconjunctivitis [30] and
eczema [40] in centres from lower-income countries,
than in centres from countries with higher GNI per
capita.
The present analysis of ISAAC Phase Three demon-
strates that the inverse association of sibship size with
these ‘allergic’ diseases is largely confined to higher-
income countries, plausibly because the contribution of
atopic mechanisms to asthma, rhinoconjunctivitis and
eczema is much greater in affluent populations. In con-
trast, the new observations of greater symptom severity
among children from larger families seem to be a more
consistent phenomenon worldwide and deserve further
exploration and explanation.
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yam), PS Suresh Babu (Davangere); Indonesia: CB Kar-
tasasmita (Bandung), P Konthen (Bali), W Suprihati
(Semarang); Iran: M-R Masjedi* (Rasht, Tehran); Isle of
Man: A Steriu (Isle of Man); Japan: H Odajima
(Fukuoka); Kuwait: JA al-Momen (Kuwait); Kyrgyzstan:
C Imanalieva* (Balykchi, Bishkek); Lithuania: J Ku-
dzyte* (Kaunas); Malaysia: BS Quah (Kota Bharu), KH
Teh (Alor Setar); Malta: S Montefort* (Malta); Mexico:
M Baeza-Bacab* (Merida), M Barragan-Meijueiro (Ciu-
dad de Mexico (3)), BE Del-Rıo-Navarro (Ciudad de
Mexico (1)), R Garcıa-Almaraz (Ciudad Victoria), SN
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Gonzalez-Dıaz (Monterrey), FJ Linares-Zapien (Toluca),
JV Merida-Palacio (Mexicali Valley), N Ramırez-Chano-
na (Ciudad de Mexico (4)), S Romero-Tapia (Villaher-
mosa), I Romieu (Cuernavaca); Morocco: Z Bouayad*
(Boulmene, Casablanca, Marrakech); New Zealand: MI
Asher* (Auckland), R MacKay (Nelson), C Moyes (Bay of
Plenty), P Pattemore (Christchurch), N Pearce (Welling-
ton); Nigeria: BO Onadeko (Ibadan); Panama: G Cukier*
(David-Panama); Peru: P Chiarella* (Lima); Philippines:
F Cua-Lim* (Metro Manila); Poland: A Bre^borowicz (Poz-
nan), G Lis* (Krakow); Portugal: R Ca^mara (Funchal), JM
Lopes dos Santos (Porto), C Nunes (Portimao), JE Rosado
Pinto* (Lisbon); Samoa: P Fuimaono (Apia); Singapore:
DYT Goh (Singapore); South Africa: HJ Zar* (Cape
Town); South Korea: H-B Lee* (Provincial Korea, Seoul);
Spain: A Blanco-Quiros (Valladolid), RM Busquets (Bar-
celona), I Carvajal-Urue~na (Asturias), G Garcıa-Hernan-
dez (Madrid), L Garcıa-Marcos* (Cartagena), C Gonzalez
Dıaz (Bilbao), A Lopez-Silvarrey Varela (A Coru~na), MM
Morales-Suarez-Varela (Valencia), EG Perez-Yarza (San
Sebastian); Sudan: OAA Musa (Khartoum); Sultanate of
Oman: O Al-Rawas* (Al-Khod); Syrian Arab Republic: S
Mohammad* (Tartous), Y Mohammad (Lattakia), K Tab-
bah (Aleppo); Taiwan: J-L Huang* (Taipei), C-C Kao
(Taoyuan); Thailand: M Trakultivakorn (Chiang Mai), P
Vichyanond* (Bangkok); Tokelau: T Iosefa* (Tokelau);
USA: HH Windom (Sarasota); United Kingdom: M Burr
(Wales)†, D Strachan (Surrey/Sussex); Uruguay: D Hol-
gado* (Montevideo), MC Lapides (Paysandu); Venezuela:
O Aldrey* (Caracas).
*National Coordinator †Deceased.
ISAAC Phase Three National Coordinators not identified
above
Canada: M Sears; Channel Islands: HR Anderson; Chile:
V Aguirre; Croatia: V Ahel; Hong Kong: CKW Lai;
India: J Shah; Indonesia: K Baratawidjaja; Isle of Man:
HR Anderson; Samoa: N Tuuau-Potai; Singapore: B-W
Lee; Sudan: A El Sony.
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